Navigation Links
MU researchers develop radioactive nanoparticles that target cancer cells
Date:5/21/2013

COLUMBIA, Mo. Cancers of all types become most deadly when they metastasize and spread tumors throughout the body. Once cancer has reached this stage, it becomes very difficult for doctors to locate and treat the numerous tumors that can develop. Now, researchers at the University of Missouri have found a way to create radioactive nanoparticles that target lymphoma tumor cells wherever they may be in the body. Michael Lewis, an associate professor of oncology in the MU College of Veterinary Medicine, says being able to target secondary tumors is vital to successfully treating patients with progressive cancers.

"Depending on the type of cancer, primary tumors usually are not the cause of death for cancer patients," Lewis said. "If a cancer metastasizes, or spreads creating hard-to-find tumors, it often becomes fatal. Having a way to identify and shrink these secondary tumors is of utmost importance when fighting to save people with these diseases."

In an effort to find a way to locate and kill secondary tumors, Lewis, in collaboration with J. David Robertson, director of research at the MU Research Reactor and professor of chemistry in the College of Arts and Science, have successfully created nanoparticles made of a radioactive form of the element lutetium. The MU scientists then covered the lutetium nanoparticles with gold shells and attached targeting agents.

In previous research, Lewis has already proven the effectiveness of similar targeting agents in mice and dogs suffering from tumors. In that research, the targeting agents were attached to single radioactive atoms that were introduced into the bodies of animals with cancer. The targeting agents were able to seek out the tumors existing within the animals, which were then revealed through radio-imaging of those animals.

In their current research, the MU scientists have shown the targeting agents can deliver the new radioactive lutetium nanoparticles to lymphoma tumor cells without attaching to and damaging healthy cells in the process. Robertson says this is an important step toward developing therapies for lymphoma and other advanced-stage cancers.

"The ability to deliver multiple radioactive atoms to individual cancer cells should greatly increase our ability to selectively kill these cells," Robertson said. "We are very optimistic about the synergy of combining the targeting strategy developed in Dr. Lewis's lab with our work on new radioactive nanoparticles."

Lewis has been invited to present his research at the City of Hope National Medical Center this June in Duarte, Calif.

This study is an example of the collaborative research taking place in the One Health, One Medicine area of Mizzou Advantage. The early-stage results of this research are promising. If additional studies, including animal studies, are successful within the next few years, the researchers will request permission from the federal government to begin human drug development. After this status has been granted, Lewis and Robertson may conduct human clinical trials with the hope of developing new treatments.

Lewis also is a principal investigator in the Research Service at the Harry S. Truman Memorial Veterans' Hospital. This research was supported by awards from the National Cancer Institute and the Department of Veterans Affairs as well as resources made available by Department of Veterans Affairs through use of facilities at the Harry S. Truman Memorial Veterans' Hospital in Columbia, Mo.


'/>"/>

Contact: Nathan Hurst
hurstn@missouri.edu
573-882-6217
University of Missouri-Columbia
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
3. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
4. UNH researchers find African farmers need better climate change data to improve farming practices
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. Researchers uncover molecular pathway through which common yeast becomes fungal pathogen
7. Researchers print live cells with a standard inkjet printer
8. Columbia Engineering and Penn researchers increase speed of single-molecule measurements
9. Researchers reveal how a single gene mutation leads to uncontrolled obesity
10. Researchers discover novel therapy for Crohns disease
11. New paper by Notre Dame researchers describes method for cleaning up nuclear waste
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Vigilant Solutions , a vehicle location ... announced today the appointment of retired FBI special agent ... business development. Mr. Sheridan brings more than ... focus on the aviation transportation sector, to his new ... Sheridan served as the Aviation Liaison Agent Coordinator (ALAC) ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/7/2017)... March 7, 2017   HireVue , the leading ... companies identify the best talent, faster, today announced the ... Officer (CSO) and Diana Kucer as Chief ... seasoned executive team poised to drive continued growth in ... a year of record bookings in 2017. ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... Research and Markets has announced the ... to their offering. ... The Global Market for Bioproducts Should Reach ... a CAGR of 8.9%, This research report ... seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and ...
(Date:3/23/2017)... Colo. , March 23, 2017  GlobeImmune, Inc. ... agreement for the sale of 12,835,490 shares of its ... NantWorks  ecosystem of companies. In connection with the sale of ... $100,000 in cash and issue to GlobeImmune 200,000 shares, ... stock. "We are pleased to enter ...
(Date:3/23/2017)... SEATTLE , March 23, 2017 ... translational development of novel therapies in immuno-oncology, today ... to lead" small molecule compounds that activate interferon ... (RLR) pathways and demonstrate immune-mediated tumor regression in ... in the study who demonstrated complete tumor regression ...
(Date:3/23/2017)... Colo. , March 23, 2017  Agriculture technology ... Series A financing and note conversion to commercialize its ... Planet is focused on developing products that are simultaneously ... $30 million in the last 18 months. This latest ... North Bridge Venture Partners. The company,s ...
Breaking Biology Technology: